Inka Health Corp., a wholly-owned subsidiary of Onco-Innovations Limited (CBOE:ONCO), announced the launch of a global consortium dedicated to advancing artificial intelligence applications in oncology research. The initiative, named Predicting Oncology Outcomes using Multimodal AI (PROmAI), represents what the company describes as a foundational step toward shaping collaboration at the intersection of AI and cancer research.
Consortium Structure and Objectives
The PROmAI Consortium aims to unite leading pharmaceutical companies, academic institutions, and data science experts in a pre-competitive collaboration focused on improving predictive modeling in cancer research and development. According to the announcement, the initiative is designed to serve as a platform for high-impact, multi-stakeholder innovation in clinically-relevant AI by fostering early alignment among scientific, clinical, and industry leaders.
The consortium seeks to overcome what Inka Health characterizes as "long-standing silos that have limited the translational utility of AI in oncology." The initiative will focus on developing and validating next-generation AI approaches that integrate real-world and clinical trial data spanning molecular, imaging, clinical, and other multimodal sources.
Technical Focus Areas
The PROmAI Consortium will concentrate on enhancing four key aspects of AI in translational oncology: predictive accuracy, interpretability, transportability, and regulatory relevance. The company emphasizes that this approach is particularly critical in oncology, where heterogeneity across patient populations and data types continues to challenge conventional modeling techniques.
By creating what the company describes as a "trusted environment for cross-sector research," the consortium aims to accelerate progress toward more personalized, cost-effective, and outcomes-driven cancer care. The initiative also intends to contribute to evolving standards around AI transparency, utility, and trustworthiness in medical research.
Strategic Vision and Leadership
Paul Arora, Co-Founder of Inka Health, stated that the initiative reflects the company's belief that "the next generation of AI in medicine won't be defined by algorithms alone, but by how well we embed those algorithms into the real-world complexities of drug development and patient care."
Arora described PROmAI as "a natural evolution of Inka Health's mission to lead in clinically credible, scientifically grounded AI innovation," adding that the company hopes to be "at the forefront of not only building better models - but also in shaping how AI can responsibly and reliably influence oncology research at scale."
Technology Platform
Inka Health operates through its proprietary platform, SynoGraph, which leverages AI-powered causal inference to identify cancer patients most likely to respond to specific treatments. The platform integrates diverse multimodal medical data, including genomics, transcriptomics, and proteomics, to uncover insights for optimizing treatment decisions and clinical trial design.
Current Status and Next Steps
The initiative is currently in its formative phase, with formal discussions underway with prospective founding members. The company indicated that additional announcements will be made as key participants confirm their involvement and collaborative plans advance.
PROmAI represents what Onco-Innovations characterizes as a strategic milestone in the company's innovation mission, which includes developing AI-driven solutions to improve patient outcomes and streamline the oncology drug development lifecycle. The initiative also marks a step toward establishing Inka Health as what the company describes as "a central convenor of cross-disciplinary innovation" in oncology.
